Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
DETERMINATION OF VARIOUS CYTOKINES AND TYPE III PROCOLLAGEN AMINOPEPTIDE LEVELS IN BRONCHOALVEOLARAVAGE FLUID OF THE PATIENTS WITH PULMONARY FIBROSIS: INVERSE CORRELATION BETWEEN TYPE III PROCOLLAGEN AMINOPEPTIDE AND INTERFERON-γ IN PROGRESSIVE PATIENTS
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients
Adjuvant high‐dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease
Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II-III treated with intralesional interferon-α 2b
m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon
